MXPA02008697A - Uso de antagonistas de interleucina-6 para el tratamiento de enfermedades caracterizadas por altos niveles de aromatasa. - Google Patents
Uso de antagonistas de interleucina-6 para el tratamiento de enfermedades caracterizadas por altos niveles de aromatasa.Info
- Publication number
- MXPA02008697A MXPA02008697A MXPA02008697A MXPA02008697A MXPA02008697A MX PA02008697 A MXPA02008697 A MX PA02008697A MX PA02008697 A MXPA02008697 A MX PA02008697A MX PA02008697 A MXPA02008697 A MX PA02008697A MX PA02008697 A MXPA02008697 A MX PA02008697A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- aromatase
- preparation
- treatment
- medicinal agent
- Prior art date
Links
- 108010078554 Aromatase Proteins 0.000 title claims abstract description 64
- 102000014654 Aromatase Human genes 0.000 title claims abstract description 64
- 201000010099 disease Diseases 0.000 title claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 10
- 229940127448 Interleukin-6 Antagonists Drugs 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 27
- 230000001419 dependent effect Effects 0.000 claims abstract description 14
- 229940088597 hormone Drugs 0.000 claims abstract description 11
- 239000005556 hormone Substances 0.000 claims abstract description 11
- 239000005557 antagonist Substances 0.000 claims abstract description 6
- 239000003112 inhibitor Substances 0.000 claims abstract description 6
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract description 4
- 229940116886 human interleukin-6 Drugs 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims description 65
- 150000001875 compounds Chemical class 0.000 claims description 34
- 208000026310 Breast neoplasm Diseases 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 229940011871 estrogen Drugs 0.000 claims description 24
- 239000000262 estrogen Substances 0.000 claims description 24
- 108700013903 SANT-7 Proteins 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 21
- 230000015572 biosynthetic process Effects 0.000 claims description 17
- 238000003786 synthesis reaction Methods 0.000 claims description 17
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 16
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 16
- 229960003399 estrone Drugs 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 102000009522 Estradiol Dehydrogenases Human genes 0.000 claims description 15
- 108010073922 Estradiol Dehydrogenases Proteins 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 102100038021 Steryl-sulfatase Human genes 0.000 claims description 5
- 108010005041 estrone sulfatase Proteins 0.000 claims description 5
- 230000001833 anti-estrogenic effect Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 abstract description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 50
- 108090001005 Interleukin-6 Proteins 0.000 description 50
- 229940100601 interleukin-6 Drugs 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 19
- 206010006187 Breast cancer Diseases 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 11
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 10
- 229960005471 androstenedione Drugs 0.000 description 9
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 229960005309 estradiol Drugs 0.000 description 8
- 229930182833 estradiol Natural products 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 239000003886 aromatase inhibitor Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229940122815 Aromatase inhibitor Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 229960003437 aminoglutethimide Drugs 0.000 description 3
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 3
- -1 call it Proteins 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 229940046844 aromatase inhibitors Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 108010017360 estrone sulfotransferase Proteins 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 201000004002 Aromatase excess syndrome Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000004896 Sulfotransferases Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091006091 regulatory enzymes Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000010009 steroidogenesis Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2000/000072 WO2001066131A1 (en) | 2000-03-06 | 2000-03-06 | Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02008697A true MXPA02008697A (es) | 2003-04-14 |
Family
ID=11133493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02008697A MXPA02008697A (es) | 2000-03-06 | 2000-03-06 | Uso de antagonistas de interleucina-6 para el tratamiento de enfermedades caracterizadas por altos niveles de aromatasa. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7160860B2 (https=) |
| EP (1) | EP1261367B1 (https=) |
| JP (1) | JP2003525906A (https=) |
| KR (1) | KR100694005B1 (https=) |
| AT (1) | ATE295735T1 (https=) |
| AU (1) | AU2000233235A1 (https=) |
| CA (1) | CA2400711A1 (https=) |
| CZ (1) | CZ20022760A3 (https=) |
| DE (1) | DE60020269T2 (https=) |
| DK (1) | DK1261367T3 (https=) |
| ES (1) | ES2241583T3 (https=) |
| HU (1) | HUP0300117A3 (https=) |
| MX (1) | MXPA02008697A (https=) |
| PL (1) | PL356846A1 (https=) |
| PT (1) | PT1261367E (https=) |
| SK (1) | SK12412002A3 (https=) |
| WO (1) | WO2001066131A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6793678B2 (en) | 2002-06-27 | 2004-09-21 | Depuy Acromed, Inc. | Prosthetic intervertebral motion disc having dampening |
| US8105382B2 (en) | 2006-12-07 | 2012-01-31 | Interventional Spine, Inc. | Intervertebral implant |
| US8900307B2 (en) | 2007-06-26 | 2014-12-02 | DePuy Synthes Products, LLC | Highly lordosed fusion cage |
| EP2471493A1 (en) | 2008-01-17 | 2012-07-04 | Synthes GmbH | An expandable intervertebral implant and associated method of manufacturing the same |
| CN102036623A (zh) | 2008-04-05 | 2011-04-27 | 斯恩蒂斯有限公司 | 可膨胀的椎间植入体 |
| US9526620B2 (en) | 2009-03-30 | 2016-12-27 | DePuy Synthes Products, Inc. | Zero profile spinal fusion cage |
| US9393129B2 (en) | 2009-12-10 | 2016-07-19 | DePuy Synthes Products, Inc. | Bellows-like expandable interbody fusion cage |
| US8979860B2 (en) | 2010-06-24 | 2015-03-17 | DePuy Synthes Products. LLC | Enhanced cage insertion device |
| US9282979B2 (en) | 2010-06-24 | 2016-03-15 | DePuy Synthes Products, Inc. | Instruments and methods for non-parallel disc space preparation |
| AU2011271465B2 (en) | 2010-06-29 | 2015-03-19 | Synthes Gmbh | Distractible intervertebral implant |
| US9402732B2 (en) | 2010-10-11 | 2016-08-02 | DePuy Synthes Products, Inc. | Expandable interspinous process spacer implant |
| US8394129B2 (en) | 2011-03-10 | 2013-03-12 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
| US8518087B2 (en) | 2011-03-10 | 2013-08-27 | Interventional Spine, Inc. | Method and apparatus for minimally invasive insertion of intervertebral implants |
| WO2014018098A1 (en) | 2012-07-26 | 2014-01-30 | DePuy Synthes Products, LLC | Expandable implant |
| US9717601B2 (en) | 2013-02-28 | 2017-08-01 | DePuy Synthes Products, Inc. | Expandable intervertebral implant, system, kit and method |
| US9522070B2 (en) | 2013-03-07 | 2016-12-20 | Interventional Spine, Inc. | Intervertebral implant |
| US11426290B2 (en) | 2015-03-06 | 2022-08-30 | DePuy Synthes Products, Inc. | Expandable intervertebral implant, system, kit and method |
| US9913727B2 (en) | 2015-07-02 | 2018-03-13 | Medos International Sarl | Expandable implant |
| WO2018002715A2 (en) | 2016-06-28 | 2018-01-04 | Eit Emerging Implant Technologies Gmbh | Expandable and angularly adjustable articulating intervertebral cages |
| EP3474783B1 (en) | 2016-06-28 | 2023-05-03 | Eit Emerging Implant Technologies GmbH | Expandable, angularly adjustable intervertebral cages |
| US10537436B2 (en) | 2016-11-01 | 2020-01-21 | DePuy Synthes Products, Inc. | Curved expandable cage |
| US10888433B2 (en) | 2016-12-14 | 2021-01-12 | DePuy Synthes Products, Inc. | Intervertebral implant inserter and related methods |
| US10398563B2 (en) | 2017-05-08 | 2019-09-03 | Medos International Sarl | Expandable cage |
| US11344424B2 (en) | 2017-06-14 | 2022-05-31 | Medos International Sarl | Expandable intervertebral implant and related methods |
| US10940016B2 (en) | 2017-07-05 | 2021-03-09 | Medos International Sarl | Expandable intervertebral fusion cage |
| US11446156B2 (en) | 2018-10-25 | 2022-09-20 | Medos International Sarl | Expandable intervertebral implant, inserter instrument, and related methods |
| US11426286B2 (en) | 2020-03-06 | 2022-08-30 | Eit Emerging Implant Technologies Gmbh | Expandable intervertebral implant |
| US11850160B2 (en) | 2021-03-26 | 2023-12-26 | Medos International Sarl | Expandable lordotic intervertebral fusion cage |
| US11752009B2 (en) | 2021-04-06 | 2023-09-12 | Medos International Sarl | Expandable intervertebral fusion cage |
| US12090064B2 (en) | 2022-03-01 | 2024-09-17 | Medos International Sarl | Stabilization members for expandable intervertebral implants, and related systems and methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1276555B1 (it) * | 1995-04-28 | 1997-11-03 | Angeletti P Ist Richerche Bio | Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni |
| IT1285790B1 (it) * | 1996-09-24 | 1998-06-24 | Angeletti P Ist Richerche Bio | Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o |
| GB9621095D0 (en) * | 1996-10-09 | 1996-11-27 | Imperial College | Novel system |
| US7205280B2 (en) * | 1998-03-11 | 2007-04-17 | Cognosci, Inc. | Methods of suppressing microglial activation |
-
2000
- 2000-03-06 DE DE60020269T patent/DE60020269T2/de not_active Expired - Fee Related
- 2000-03-06 CZ CZ20022760A patent/CZ20022760A3/cs unknown
- 2000-03-06 MX MXPA02008697A patent/MXPA02008697A/es active IP Right Grant
- 2000-03-06 EP EP00911250A patent/EP1261367B1/en not_active Expired - Lifetime
- 2000-03-06 ES ES00911250T patent/ES2241583T3/es not_active Expired - Lifetime
- 2000-03-06 DK DK00911250T patent/DK1261367T3/da active
- 2000-03-06 PT PT00911250T patent/PT1261367E/pt unknown
- 2000-03-06 CA CA002400711A patent/CA2400711A1/en not_active Abandoned
- 2000-03-06 WO PCT/IT2000/000072 patent/WO2001066131A1/en not_active Ceased
- 2000-03-06 KR KR1020027011558A patent/KR100694005B1/ko not_active Expired - Fee Related
- 2000-03-06 HU HU0300117A patent/HUP0300117A3/hu unknown
- 2000-03-06 AT AT00911250T patent/ATE295735T1/de not_active IP Right Cessation
- 2000-03-06 PL PL00356846A patent/PL356846A1/xx not_active IP Right Cessation
- 2000-03-06 AU AU2000233235A patent/AU2000233235A1/en not_active Abandoned
- 2000-03-06 SK SK1241-2002A patent/SK12412002A3/sk unknown
- 2000-03-06 JP JP2001564783A patent/JP2003525906A/ja not_active Withdrawn
-
2004
- 2004-11-16 US US10/988,628 patent/US7160860B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT1261367E (pt) | 2005-09-30 |
| HUP0300117A3 (en) | 2005-09-28 |
| KR20020079984A (ko) | 2002-10-21 |
| HUP0300117A2 (hu) | 2003-04-28 |
| WO2001066131A1 (en) | 2001-09-13 |
| CZ20022760A3 (cs) | 2003-03-12 |
| KR100694005B1 (ko) | 2007-03-12 |
| AU2000233235A1 (en) | 2001-09-17 |
| ATE295735T1 (de) | 2005-06-15 |
| DE60020269D1 (de) | 2005-06-23 |
| EP1261367B1 (en) | 2005-05-18 |
| DK1261367T3 (da) | 2005-09-12 |
| EP1261367A1 (en) | 2002-12-04 |
| US7160860B2 (en) | 2007-01-09 |
| US20050090443A1 (en) | 2005-04-28 |
| JP2003525906A (ja) | 2003-09-02 |
| ES2241583T3 (es) | 2005-11-01 |
| CA2400711A1 (en) | 2001-09-13 |
| DE60020269T2 (de) | 2006-01-19 |
| SK12412002A3 (sk) | 2002-12-03 |
| PL356846A1 (en) | 2004-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02008697A (es) | Uso de antagonistas de interleucina-6 para el tratamiento de enfermedades caracterizadas por altos niveles de aromatasa. | |
| Reed et al. | Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis | |
| Bulun et al. | Aromatase in aging women | |
| Saxena et al. | Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells | |
| Raber et al. | Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response. | |
| KR20140038382A (ko) | 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제 | |
| Qu et al. | Pathological niche environment transforms dermal stem cells to keloid stem cells: a hypothesis of keloid formation and development | |
| Lu et al. | Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. | |
| Hsu et al. | Influence of interleukin-6 on the invasiveness of human colorectal carcinoma | |
| JPH05504548A (ja) | インターロイキン―２とヒスタミン、その類似体又はｈ↓２―受容体アゴニストを含む抗腫瘍性製剤 | |
| Gu et al. | Effect of IFN-gamma and dexamethasone on TGF-beta~ 1-induced human fetal lung fibroblast-myofibroblast differentiation | |
| JP2002504102A (ja) | 糖尿病治療のためのレプチン拮抗物質の使用 | |
| Szende et al. | Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin | |
| US10081810B2 (en) | C-Rel-specific siRNA and its use for preventing and treating autoimmune psoriasis | |
| Wang et al. | Effects of human breast stromal cells on conjugated linoleic acid (CLA) modulated vascular endothelial growth factor-A (VEGF-A) expression in MCF-7 cells | |
| WO2004080477A1 (en) | Aplidine for multiple myeloma treatment | |
| Garcia et al. | Clinical and immunomodulatory effects of bevacizumab and low‐dose interleukin‐2 in patients with metastatic renal cell carcinoma: results from a phase II trial | |
| Tanaka et al. | Growth suppression and astrocytic differentiation of glioma cells by interleukin-1 | |
| Schmidt et al. | A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-α in patients with metastatic melanoma | |
| Arany et al. | Interferon regulates expression of mda-6/WAF1/CIP1 and cyclin-dependent kinases independently from p53 in B16 murine melanoma cells | |
| CN116211860B (zh) | Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物 | |
| Wang et al. | Sensitization by interleukin‐lα of carboplatinum anti‐tumor activity against human ovarian (NIH: OVCAR‐3) carcinoma cells in vitro and in vivo | |
| CN113318105B (zh) | 含Binimetinib的用于治疗结肠癌的药物组合物及其应用 | |
| Baral et al. | The effect of tamoxifen on the immune response | |
| KR101169850B1 (ko) | 트로락스를 포함하는 골 대사성 질환 또는 골 전이성 암 질환 예방 및 치료용 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |